Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22850
Title: Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments.
Authors: Perini, Marcos V;Dmello, Rhynelle S;Nero, Tracy L;Chand, Ashwini L
Affiliation: Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Biochemistry and Molecular Biology, Bio21 Institute, University of Melbourne, Parkville, Victoria, Australia
School of Cancer Medicine, La Trobe University, Heidelberg, Victoria, Australia
Cancer and Inflammation Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
Issue Date: 12-Mar-2020
EDate: 2020-03-12
Citation: Pharmacology & therapeutics 2020; online first: 12 March
Abstract: G-protein-coupled receptors (GPCRs) are the largest and most diverse group of cellular membrane receptors identified and characterized. It is estimated that 30 to 50% of marketed drugs target these receptors. The angiotensin II receptor type 1 (AT1R) is a GPCR which signals in response to systemic alterations of the peptide hormone angiotensin II (AngII) in circulation. The enzyme responsible for converting AngI to AngII is the angiotensin-converting enzyme (ACE). Specific inhibitors for the AT1R (more commonly known as AT1R blockers or antagonists) and ACE are well characterized for their effects on the cardiovascular system. Combined with the extensive clinical data available on patient tolerance of AT1R blockers (ARBs) and ACE inhibitors (ACEIs), as well as their non-classical roles in cancer, the notion of repurposing this class of medications as cancer treatment(s) is explored in the current review. Given that AngII-dependent AT1R activity directly regulates angiogenesis, remodeling of vasculature, pro-inflammatory responses, stem cell programming and hematopoiesis, and electrolyte balance; the modulation of these processes with pharmacologically well characterized medications could present a valuable complementary treatment option for cancer patients.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22850
DOI: 10.1016/j.pharmthera.2020.107527
ORCID: 0000-0002-0165-1564
0000-0002-1245-729X
PubMed URL: 32173557
Type: Journal Article
Review
Subjects: ACE inhibitors
AT1R
AT1R blockers
Angiotensin II
Cancer
Immunotherapy
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.